# Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment

> **NCT07464340** · PHASE1 · COMPLETED · sponsor: **Zodiac Produtos Farmaceuticos S.A.** · enrollment: 68 (actual)

## Conditions studied

- Bioequivalence Study in Healthy Subjects

## Interventions

- **DRUG:** Rivastigmine TDS 9,5 mg/24 h
- **DRUG:** Exelon® 9.5 mg/24 h

## Key facts

- **NCT ID:** NCT07464340
- **Lead sponsor:** Zodiac Produtos Farmaceuticos S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-12
- **Primary completion:** 2023-06-06
- **Final completion:** 2023-07-03
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07464340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07464340, "Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07464340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*